High levels of BCL-2 universally found in chronic lymphocytic leukaemia (CLL), especially those refractory to chemotherapy, can potentially now be targeted therapeutically with ABT-737, a small molecule inhibitor of BCL-2 and BCL-X L . The structural analogue ABT-263 (Navitoclax) is under clinical development and has shown encouraging single-agent activity in vivo.
1 Although single-agent efficacy has been demonstrated, responses were not complete. Thus, further therapeutic improvements remain necessary and outcomes for CLL patients may be improved by combination of ABT-737 with other agents, particularly those that activate the intrinsic apoptotic pathway. Many conventional chemotherapeutic agents that may be considered for combination with ABT-737 are genotoxic and indirectly trigger apoptosis by damaging DNA, potentially causing permanent damage that could contribute to the development of chemoresistance and/or inducing secondary malignancies. In contrast, histone deacetylase inhibitors (HDACi) effect reversible epigenetic changes and induce tumour cell apoptosis. We have found that in mouse models of B-cell lymphoma overexpressing BCL-2, HDACi sensitise these cells to sub-lethal doses of ABT-737. 2, 3 These studies provided pre-clinical evidence that HDACi may be a useful agent to combine with ABT-737 and may synergise with prolonged administration of ABT-737 at doses that minimise toxicities such as thrombocytopenia. To test this hypothesis, we evaluated the sensitivity of primary CLL samples to co-incubation with increasing concentrations of ABT-737 and the HDACi, vorinostat and panobinostat.
Peripheral blood mononuclear cells (PBMCs) were collected from patients with CLL referred to the Peter MacCallum Cancer Centre. Patient selection was based on a confirmed diagnosis of CLL, a peripheral blood WBC count 420 Â 10 9 /l and a treatmentfree interval of at least 6 months before sample acquisition. Additional clinical characteristics of patients are given in Table 1 . Informed consent was obtained and experiments were conducted in accordance with institutional ethics policy after study approval. Purified PBMCs were cultured in the presence of drugs, alone or in combination, for 24 h (vorinostat þ ABT-737) or 48 h (panobinostat þ ABT-737). Unexpectedly, in contrast to our previous findings using murine lymphoma cells, we found that neither vorinostat nor panobinostat synergised with ABT-737 in inducing apoptosis of CLL cells in vitro (Figure 1a) . We, therefore, carefully reviewed the CLL responses to each agent alone. The lack of a significant response to vorinostat or panobinostat alone (Figure 1b ): (i) was consistent with the observed high levels of expression of BCL-2 in our CLL samples ( Figure 1c) ; (ii) was not due to inactivity of HDACi in the CLL cells since western blotting demonstrated a clear time-dependent increase in histone H3 acetylation following exposure to vorinostat ( Figure 1d ); (iii) was consistent with our previous results for murine lymphoma cells overexpressing BCL-2.
1 As ABT-737 alone ( Figure 1e ) exhibited a range in potency towards CLL comparable to reported results from others, 4 we surmised that the lack of synergy between the HDACi and ABT-737 may be due to a defect in the ability of HDACi to promote apoptotic signalling upstream of BCL-2.
In murine lymphoma cells, we found that the BH3-only protein BMF, a potent activator of the intrinsic apoptotic signalling pathway, was significantly upregulated within 24 h exposure to HDACi and was essential for synergy with ABT-737. 3 As there was no synergistic response to ABT-737 combined with either vorinostat or panobinostat, we examined the transcriptional response of BMF to vorinostat, within the 24 h time frame. A reverse transcription --multiplex ligation-dependent probe amplification (RT --MLPA) screen of apoptotic gene expression in Letters to the Editor CLL samples versus CCRF-CEM, a human acute T-cell leukaemia line shown previously to respond to HDACi, 5 was performed. This analysis indicated that, for CLL cells, 8-hr incubation in the presence of 2.5 mM vorinostat resulted in BMF mRNA levels similar to cells incubated for 8 h in the absence of vorinostat (mean fold change 1.1). In contrast, BMF expression was more than tenfold greater in vorinostat-treated CCRF --CEM cells (Figure 1f ), similar to our observations in murine B lymphoma cells. 3 Quantitative realtime PCR (QRT --PCR) of BMF and H1F0, another gene known to be upregulated by HDAC inhibitors, 5 was performed on CLL samples and CCRF --CEM cells following incubation with 2.5 mM vorinostat for 0, 4, 8, 16 and 24 h. As in the RT --MLPA screen, a significant increase in BMF expression in response to HDACi was observed only in CCRF --CEM cells and not in any of the 12 CLL samples examined (Figure 1g ). HDACi activity in CLL cells was confirmed by up-regulation of H1F0 (Figure 1g) . To exclude the possibility that the lack of response to vorinostat in CLL cells was simply due to having used insufficient, but clinically achievable, doses, we performed QRT --PCR for BMF expression after exposure to 0, 2.5, 5, 10 and 25 mM vorinostat (Figure 1h) . However, even when the dose of vorinostat was increased tenfold, no induction of BMF occurred in CLL cells. The induction of BMF in CCRF --CEM in response to 5, 10 and 25 mM vorinostat (fold change: 33.9 ± 9.2, 36.8±9.1, 35.1±9.6, respectively) was not substantially increased above the level of induction observed with 2.5 mM (fold change: 28.0 ± 5.0), indicating that pharmacologically relevant doses of vorinostat were sufficient for maximal upregulation of BMF.
HDACi are thought to facilitate BMF gene expression by acetylation of histones H3 and H4 in the BMF promoter region. 3, 6 We found that vorinostat was still able to elicit significant global acetylation of histones in CLL cells (Figure 1d) , indicating that the inability of vorinostat to alter BMF expression levels in CLL may be due to specific aberrations of the BMF locus. However, it has also been reported that basal expression levels of BMF in CLL cells are often higher than in normal B cells. 7 In our QRT --PCR analyses we found that in untreated CLL samples the difference in Ct values between BMF and our reference gene was much less than that for untreated control cells, suggesting that the amount of BMF mRNA present in the CLL samples was greater than our control cells. This, combined with our dose-response data suggesting that there may 
ABT-737 Dose (nM) % Viable cells (7AAD-)

U T U T U T U T U T 0hr 4hr 8hr 16hr 24hr U -untreated T -cells treated with 2.5uM
Vorinostat for indicated times be a fixed maximum degree of BMF upregulation that can be induced (Figure 1h ), raises the possibility that HDACi are unable to upregulate BMF in CLL cells beyond maximal levels. If this is true, the abnormally high levels of BMF, while readily tolerated (perhaps owing to high BCL-2 levels), may contribute to the exquisite sensitivity of CLL to ABT-737, since BMF bound to BCL-2 would diminish the 'free' pool of BCL-2 that might be bound by ABT-737, thereby lowering the threshold for activation of BAX or BAK. Because of the ability of HDACi to alter the expression of a number of genes other than BMF HDACi may yet be useful agents for CLL therapy in combination with drugs targeting other important signalling pathways, such as the extrinsic death receptor apoptosis pathway. 8 However, irrespective of the mechanism underlying the failure of vorinostat to upregulate BMF expression, in combination with ABT-737, vorinostat provides no added therapeutic activity for the primary CLL cells tested. Figure 1 . HDAC inhibitors and ABT-737 fail to synergize in CLL. (a) PBMCs (1 Â 10 6 /ml) from CLL patients (nX9) were cultured in the presence of drugs (alone or in combination) for 24 h (vorinostat þ ABT-737) or 48 h (panobinostat þ ABT-737). PBMCs were washed with PBS, stained with 7AAD (2 --5 mg/ml) and the proportion of viable cells determined by flow cytometry using a BD LSRII or FACS Canto instrument. (b) The percent viability determined for vorinostat alone (24 h) and panobinostat alone (48 h) were normalised to account for varying levels of spontaneous (background) cell death using the formula: 1-((% apoptosis in treated cells --% apoptosis in untreated cells)/(100 --% apoposis in untreated cells)). Each grey line represents an individual CLL sample. The heavy black line represents the mean. (c) Expression of Bcl-2 family pro-survival proteins was determined by western blotting performed on untreated PBMCs and CEM cells. For each sample 40 mg total protein was analysed. Primary antibodies used were mouse anti-human Bcl-2 (Clone 100, 1:500, Santa Cruz Biotechnology), rabbit anti-human Mcl-1 (1:1000, Cell Signalling Technology), mouse anti-human Bcl-XL (Clone H-5, 1:250, Santa Cruz Biotechnology), rat anti-human Bcl-w (Clone 16H12, 1:1000, Millipore), rabbit anti-human A1 (1:500, kindly provided by Jannie Borst), and mouse anti b-actin (Clone AC-74, 1:10000, Sigma). U266, BJLTSTERas/A1, and Eu-myc/hBcl-w cell lines were included as positive controls for, respectively, the expression of Bcl-XL, A1, and Bcl-w. 6 cells/ml) treated with either media alone or vorinostat for 8 h. A non-template and a --RT control were included, and the expression level for BMF normalised by comparison with the expression of L32. Fold change was calculated relative to treatment with 0 mM vorinostat. Three biological replicates were performed for all samples except CLL 14, for which only 2 replicates could be performed.
